We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
Read MoreHide Full Article
Editas Medicine, Inc. (EDIT - Free Report) announced that the FDA has granted Orphan Drug designation to its investigational gene-editing medicine, EDIT-301, for the treatment of beta thalassemia, a devastating disease that leads to severe anemia, organ failure and premature death.
The Orphan Drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes one that affects fewer than 200,000 individuals in the United States. The designation also includes incentives, including financial aid for clinical testing, and seven-year marketing exclusivity in the event of regulatory approval.
Per the company, the Orphan Drug tag for EDIT-301 for treating beta thalassemia underlines the urgent need for new treatment options for the given patient population.
Shares of Editas were up 4.5% in after-hours trading on Thursday following the announcement of the news. The stock has plunged 59.3% so far this year compared with the industry’s decline of 26.7%.
Image Source: Zacks Investment Research
Editas plans to begin a phase I/II study to evaluate EDIT-301 for treating transfusion-dependent beta thalassemia later in 2022.
The FDA granted Rare Pediatric Disease designation to EDIT-301 for the treatment of beta thalassemia in April 2022.
EDIT-301 is also evaluating the safety and efficacy of EDIT-301 for treating sickle cell disease (“SCD”). EDIT-301 has also been granted a Rare Pediatric Disease for treating SCD.
The company is currently enrolling participants in the phase I/II RUBY study for treating SCD and expects to begin dosing in the first half of 2022. Top-line data from the same is expected by 2022-end.
Editas’ lead pipeline candidate, EDIT-101, employs CRISPR gene editing to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness.
Last month, the company dosed the first pediatric patient in the phase I/II BRILLIANCE study evaluating EDIT-101 for the treatment of blindness due to LCA10. Currently, there is no therapy approved for treating LCA10.
An update from the BRILLIANCE study is expected in the second half of 2022.
Applied Therapeutics’ loss per share estimates have narrowed 34.1% for 2022 and 20.2% for 2023 over the past 60 days.
Earnings of Applied Therapeutics have surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion. APLT delivered an earnings surprise of 2.58% on average.
Aeglea BioTherapeutics’ loss per share estimates have narrowed 15.2% for 2022 and 16.7% for 2023 over the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47% on average.
EyePoint Pharmaceuticals’ loss per share estimates have narrowed 8.7% for 2022 and 12.5% for 2023 over the past 60 days.
Earnings of EyePoint Pharmaceuticals have surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions. EYPT delivered an earnings surprise of -5.80% on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
Editas Medicine, Inc. (EDIT - Free Report) announced that the FDA has granted Orphan Drug designation to its investigational gene-editing medicine, EDIT-301, for the treatment of beta thalassemia, a devastating disease that leads to severe anemia, organ failure and premature death.
The Orphan Drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes one that affects fewer than 200,000 individuals in the United States. The designation also includes incentives, including financial aid for clinical testing, and seven-year marketing exclusivity in the event of regulatory approval.
Per the company, the Orphan Drug tag for EDIT-301 for treating beta thalassemia underlines the urgent need for new treatment options for the given patient population.
Shares of Editas were up 4.5% in after-hours trading on Thursday following the announcement of the news. The stock has plunged 59.3% so far this year compared with the industry’s decline of 26.7%.
Image Source: Zacks Investment Research
Editas plans to begin a phase I/II study to evaluate EDIT-301 for treating transfusion-dependent beta thalassemia later in 2022.
The FDA granted Rare Pediatric Disease designation to EDIT-301 for the treatment of beta thalassemia in April 2022.
EDIT-301 is also evaluating the safety and efficacy of EDIT-301 for treating sickle cell disease (“SCD”). EDIT-301 has also been granted a Rare Pediatric Disease for treating SCD.
The company is currently enrolling participants in the phase I/II RUBY study for treating SCD and expects to begin dosing in the first half of 2022. Top-line data from the same is expected by 2022-end.
Editas’ lead pipeline candidate, EDIT-101, employs CRISPR gene editing to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness.
Last month, the company dosed the first pediatric patient in the phase I/II BRILLIANCE study evaluating EDIT-101 for the treatment of blindness due to LCA10. Currently, there is no therapy approved for treating LCA10.
An update from the BRILLIANCE study is expected in the second half of 2022.
Zacks Rank & Stocks to Consider
Editas currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Applied Therapeutics, Inc. (APLT - Free Report) , Aeglea BioTherapeutics, Inc. and EyePoint Pharmaceuticals, Inc. (EYPT - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Applied Therapeutics’ loss per share estimates have narrowed 34.1% for 2022 and 20.2% for 2023 over the past 60 days.
Earnings of Applied Therapeutics have surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion. APLT delivered an earnings surprise of 2.58% on average.
Aeglea BioTherapeutics’ loss per share estimates have narrowed 15.2% for 2022 and 16.7% for 2023 over the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47% on average.
EyePoint Pharmaceuticals’ loss per share estimates have narrowed 8.7% for 2022 and 12.5% for 2023 over the past 60 days.
Earnings of EyePoint Pharmaceuticals have surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions. EYPT delivered an earnings surprise of -5.80% on average.